Funded Tech Companies
AAVantgarde
Headquartered in Milano, AAVantgarde has funding from Amgen Ventures, Columbia University and Athos Capital.
Company Overview
Company Name
AAVantgarde
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Via Vincenzo Gioberti, 8
Milano, 20123
iT
Milano, 20123
iT
Phone
Website
Email Address
Company Background Information
Overview
AAVantgarde Bio is a clinical stage, Italian headquartered, international biotechnology company that has developed two proprietary Adeno-Associated Viral (AAV) vector platforms to address the gene therapy cargo capacity limitations of AAV vectors. This platform is being clinically validated in two Inherited Retinal Diseases; Usher1B and Stargardt disease, and the platform is expected to address the gene therapy cargo capacity limitations of AAV vectors and therefore the future pipeline could extend into many disease areas.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
11/6/2025
Financing History
Management Team
Title
Name
Email & Social
Chief Executive Officer
Natalia Misciattelli
Chief Medical Officer
Naveed Shams
Founder
Alberto Auricchio
Company Investors
- Amgen Ventures
- Columbia University
- Athos Capital
- Forbion Capital Partners
- Neva SGR
- Atlas Venture
- Sofinnova Partners
- Longwood Fund
- Sixty Degree Capital
- XGen Ventures
- CDP Venture Capital
- Schroders Capital
- Willett Advisors
Browse more funded tech companies:
Share this article
About Our VC Deals Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs